公开(公告)号：EP4408843A1

公开(公告)日：2024-08-07

申请号：EP22801649.9

申请日：2022-09-27

申请人： Viva Star Biosciences (Suzhou) Co., Ltd.

发明人： CHEN, Ping ,  JIANG, Fei ,  SUN, Peihua ,  ZHANG, Hongjian

IPC分类号： C07D471/04 ,  C07D487/04 ,  A61P3/00 ,  A61P3/10 ,  A61P19/00 ,  A61P19/02 ,  A61P19/06 ,  A61P25/16 ,  A61P25/28 ,  A61P35/00 ,  A61K31/64

CPC分类号： C07D471/04 ,  C07D487/04 ,  A61P25/28 ,  A61P25/16 ,  A61P3/00 ,  A61P3/10 ,  A61P35/00 ,  A61P19/00 ,  A61P19/02 ,  A61P19/06

公开(公告)号：EP3556371B1

公开(公告)日：2024-06-12

申请号：EP17881816.7

申请日：2017-12-13

IPC分类号： A61K9/00 ,  A61K9/08 ,  A61K47/40 ,  A61K47/26 ,  A61K47/02 ,  A61P3/10 ,  A61K31/64 ,  A61K47/50 ,  A61K9/19 ,  A61K47/69 ,  C08B37/16

CPC分类号： A61K9/08 ,  A61K31/64 ,  A61K47/02 ,  A61K47/26 ,  A61K47/40 ,  A61P3/10 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/6951 ,  C08B37/0015

公开(公告)号：EP4180045A1

公开(公告)日：2023-05-17

申请号：EP20952613.6

申请日：2020-09-02

申请人： Laboratorios Silanes, S.A. de C.V.

发明人： OLLERVIDES RUBIO, Paola Yazmín ,  ESPINOZA LEÓN, Sixto Serafín ,  CUAHUTENCOS ESCOBAR, Ernesto ,  GONZÁLEZ CANUDAS, Jorge Alejandro

IPC分类号： A61K31/64 ,  A61K31/155 ,  A61K31/401 ,  A61P3/10

摘要： This invention relates to an innovative stable immediate release drug for the treatment, control, and better management of type 2 diabetes mellitus containing a sulfonylurea such as glimepiride, a dipeptidyl peptidase-4 (DPP4) inhibitor such as vildagliptin, and a biguanidine such as metformin. At the same time, this invention allows solving a set of important technological challenges in the manufacture of said drug product due to the physicochemical properties and the difference in dosage of the synergistic combination of the drugs.

公开(公告)号：EP2249812B9

公开(公告)日：2023-03-01

申请号：EP09707868.7

申请日：2009-02-03

发明人： VALDUCCI, Roberto ,  ALIGHIERI, Tiziano ,  AVANESSIAN, Serozh

IPC分类号： A61K9/20 ,  A61K31/64

公开(公告)号：EP4117785A1

公开(公告)日：2023-01-18

申请号：EP21767126.2

申请日：2021-03-12

申请人： Simard, Marc J.

发明人： Simard, Marc J.

IPC分类号： A61P25/28 ,  A61K31/175 ,  A61K31/225 ,  A61K31/64

公开(公告)号：EP4009961A1

公开(公告)日：2022-06-15

申请号：EP20754707.6

申请日：2020-08-07

申请人： Evonik Operations GmbH

发明人： GUHA, Ashish ,  SINGH, Sonam ,  JOSHI, Shraddha ,  NIEPOTH, Peter ,  NOLLENBERGER, Kathrin ,  SURVE, Prajakta ,  HAKSAR, Priyanka

IPC分类号： A61K9/20 ,  A61K31/415 ,  A61K31/427 ,  A61K31/635 ,  A61K31/55 ,  A61K31/593 ,  A61K31/64 ,  A23L33/12

公开(公告)号：EP3996717A1

公开(公告)日：2022-05-18

申请号：EP20740268.6

申请日：2020-07-09

申请人： Genesis Pharma SA

发明人： VOGIATZIS, George

IPC分类号： A61K31/64 ,  A61K38/00 ,  A61K31/565 ,  A61P9/00

公开(公告)号：EP3978489A1

公开(公告)日：2022-04-06

申请号：EP21204857.3

申请日：2018-07-04

申请人： Inflazome Limited

发明人： COOPER, Matthew ,  MILLER, David ,  MACLEOD, Angus ,  VAN WILTENBURG, Jimmy ,  THOM, Stephen ,  ST-GALLAY, Stephen ,  SHANNON, Jonathan

IPC分类号： C07D401/14 ,  A61K31/64 ,  C07D217/22 ,  C07D223/06 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D405/04 ,  C07D405/06 ,  C07D409/04 ,  C07D239/66 ,  C07D241/18 ,  C07D451/02 ,  C07D451/14 ,  C07D205/04 ,  C07D205/12 ,  C07D207/12 ,  C07D211/54 ,  A61P37/00

摘要： The present invention relates to compounds of formula (I):

wherein Q is selected from O or S; R 1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R 1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R 1 may optionally be substituted; and R 2 is a cyclic group substituted at the α-position, wherein R 2 may optionally be further substituted.
The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP 3 .

公开(公告)号：EP3865472A1

公开(公告)日：2021-08-18

申请号：EP20212296.6

申请日：2016-06-13

申请人： ATXA Therapeutics Limited

发明人： KINSELLA, B. Therese ,  REID, Helen

IPC分类号： C07C311/58 ,  A61K31/64 ,  A61P3/10 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/08 ,  A61P13/12 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00

摘要： The invention relates to novel chemical entities that act as thromboxane (TX) A 2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A and of all other agents that act as incidental ligands of TP, including the endoperoxide prostaglandin (PG)G 2 /PGH 2 , 20-hydroxyeicosatetraenoic acid (20-HETE) and the free -radical derived isoprostanes (e.g., 8-iso-prostaglandin (PG)F 2α ), play a role. Compounds of the invention preferably include a benzenesulfonyl urea in which the benzene is substituted by a substituted biphenylyloxy group (e.g., at the 2 position) and by a nitrile group (e.g., at the 5 position), which compounds show promising results as TP-isoform selective TP antagonists.

公开(公告)号：EP3858339A1

公开(公告)日：2021-08-04

申请号：EP20214642.9

申请日：2012-12-21

申请人： Reprise Pharmaceuticals, Inc.

发明人： FRIESE, Manuel ,  SCHATTLING, Benjamin ,  STEINBACH, Karin ,  FREICHEL, Marc ,  FLOCKERZI, Veit ,  VENNEKENS, Rudi ,  MERKLER, Doron

IPC分类号： A61K31/00 ,  A61K31/05 ,  A61K31/132 ,  A61K31/196 ,  A61K31/198 ,  A61K31/352 ,  A61K31/365 ,  A61K31/4402 ,  A61K31/4453 ,  A61K31/473 ,  A61K31/565 ,  A61K31/566 ,  A61K45/06 ,  A61K31/64 ,  A61P25/00 ,  A61P25/28 ,  G01N33/50 ,  G01N33/68

摘要： The invention relates to a compound which is effective in inhibiting the function of the TRPM4 ion channel and the use of such compound in treating or preventing a neurodegenerative disease, such as Multiple Sclerosis, Parkinson's disease, Alzheimer's disease, or amyotrophic lateral sclerosis, in a subject. The invention also provides a pharmaceutical composition comprising a TRPM4 inhibitory compound. The invention further relates to in vitro methods for identifying pharmaceutically active compounds that are useful for treating or preventing a neurodegenerative disease.